Drug intelligence / Profile preview

RH-1402

Development stage: Unknown
Lead developer: Anhui Medical University

Overview

RH-1402: sourced facts only. name: "In this study, we investigated the therapeutic effect of a novel gastrin-releasing peptide receptor antagonist RH-1402 in hyperuricemia-induced kidney fibrosis and its underlying mechanisms." [PMID:38084678]; target: "In this study, we investigated the therapeutic effect of a novel gastrin-releasing peptide receptor antagonist RH-1402 in hyperuricemia-induced kidney fibrosis and its underlying mechanisms." [PMID:38084678]; developer: "School of Basic Medicine, Anhui Medical University, Hefei 230032, China; College of Life Sciences, Anhui Medical University, Hefei 230032, China." [PMID:38084678]; stage: "Pre-treatment with RH-1402 attenuated hyperuricaemia-induced renal injury, restored renal function, and suppressed renal inflammation and fibrosis." [PMID:38084678]

Targets

GRPR (Gastrin-releasing peptide receptor)

Beyond the preview

Go deeper on RH-1402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RH-1402.